HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Filip Janku Selected Research

ulixertinib

1/2018First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
1/2018Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Filip Janku Research Topics

Disease

167Neoplasms (Cancer)
10/2022 - 08/2005
13Melanoma (Melanoma, Malignant)
01/2021 - 08/2005
12Fatigue
10/2022 - 05/2014
12Breast Neoplasms (Breast Cancer)
01/2021 - 10/2004
12Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2020 - 10/2004
12Colorectal Neoplasms (Colorectal Cancer)
01/2020 - 03/2011
11Thrombocytopenia (Thrombopenia)
10/2021 - 12/2006
11Neoplasm Metastasis (Metastasis)
03/2021 - 01/2011
8Nausea
10/2022 - 05/2014
8Diarrhea
10/2022 - 12/2006
8Ovarian Neoplasms (Ovarian Cancer)
10/2021 - 03/2011
7Vomiting
10/2022 - 09/2015
7Disease Progression
01/2021 - 03/2014
7Exanthema (Rash)
01/2021 - 02/2015
7Sarcoma (Soft Tissue Sarcoma)
01/2020 - 03/2012
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2021 - 03/2013
6Neutropenia
10/2021 - 12/2006
6Triple Negative Breast Neoplasms
03/2020 - 12/2014
5Anemia
11/2018 - 12/2006
4Cholangiocarcinoma
01/2022 - 01/2013
4Carcinoma (Carcinomatosis)
01/2022 - 12/2013
4Hodgkin Disease (Hodgkin's Disease)
11/2020 - 01/2014
3Mucositis
11/2021 - 10/2016
3Hypertension (High Blood Pressure)
01/2021 - 02/2015
3Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
10/2020 - 06/2017
3Lung Neoplasms (Lung Cancer)
10/2019 - 05/2013
3Erdheim-Chester Disease
01/2019 - 06/2014
3Carcinogenesis
09/2017 - 01/2011
3Prostatic Neoplasms (Prostate Cancer)
07/2015 - 03/2014
3Hypoxia (Hypoxemia)
11/2014 - 11/2011
2Constipation
10/2022 - 10/2020
2Thyroid Neoplasms (Thyroid Cancer)
01/2022 - 01/2018
2Endometrial Neoplasms (Endometrial Cancer)
10/2021 - 05/2014
2Glioma (Gliomas)
01/2021 - 10/2020
2Rare Diseases (Rare Disease)
12/2020 - 06/2017

Drug/Important Bio-Agent (IBA)

16Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 09/2011
16Bevacizumab (Avastin)FDA Link
01/2020 - 11/2011
13DNA (Deoxyribonucleic Acid)IBA
07/2021 - 01/2011
12Cell-Free Nucleic AcidsIBA
10/2021 - 01/2015
12Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2021 - 01/2011
11EverolimusFDA Link
01/2021 - 05/2014
11Pharmaceutical PreparationsIBA
01/2019 - 11/2011
10MTOR InhibitorsIBA
11/2020 - 03/2012
8Proteins (Proteins, Gene)FDA Link
07/2021 - 05/2015
8temsirolimusFDA Link
01/2018 - 11/2011
7selinexorIBA
04/2022 - 08/2017
7VemurafenibIBA
01/2021 - 07/2014
6Carboplatin (JM8)FDA LinkGeneric
04/2022 - 06/2014
6Circulating Tumor DNAIBA
01/2022 - 05/2017
6Biomarkers (Surrogate Marker)IBA
11/2021 - 03/2013
6ErbB Receptors (EGF Receptor)IBA
01/2020 - 09/2011
6Cetuximab (Erbitux)FDA Link
01/2020 - 01/2014
6Tyrosine Kinase InhibitorsIBA
01/2020 - 03/2013
5Paclitaxel (Taxol)FDA LinkGeneric
04/2022 - 10/2004
5Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
01/2022 - 01/2016
5pembrolizumabIBA
11/2021 - 01/2020
5pazopanibFDA Link
01/2021 - 06/2015
5CytokinesIBA
01/2021 - 05/2014
5Trastuzumab (Herceptin)FDA Link
01/2021 - 10/2004
5Immune Checkpoint InhibitorsIBA
12/2020 - 12/2017
4Biological ProductsIBA
01/2022 - 06/2013
4Sorafenib (BAY 43-9006)FDA Link
01/2021 - 04/2014
4Histone Deacetylase InhibitorsIBA
11/2020 - 03/2014
4VorinostatFDA Link
11/2020 - 10/2016
4Monoclonal AntibodiesIBA
01/2020 - 03/2014
4Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2020 - 05/2014
4Estrogen ReceptorsIBA
01/2019 - 05/2015
4Phosphotransferases (Kinase)IBA
01/2019 - 09/2011
4ParaffinIBA
01/2019 - 04/2014
4Formaldehyde (Formol)FDA Link
01/2019 - 04/2014
4Lenalidomide (CC 5013)FDA Link
01/2018 - 12/2013
4Imatinib Mesylate (Gleevec)FDA Link
01/2017 - 08/2005
3Pemetrexed (MTA)FDA Link
02/2022 - 12/2006
3liposomal doxorubicin (Doxil)FDA Link
01/2022 - 11/2011
3ripretinibIBA
01/2021 - 01/2019
3CrizotinibIBA
01/2021 - 01/2018
3Hormones (Hormone)IBA
01/2021 - 05/2015
3Sirolimus (Rapamycin)FDA Link
11/2020 - 08/2015
3ivosidenibIBA
10/2020 - 01/2019
3CreatinineIBA
01/2019 - 06/2015
3TOR Serine-Threonine KinasesIBA
01/2018 - 05/2014
3Lapatinib (GW572016)FDA Link
11/2017 - 02/2015
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
07/2015 - 12/2006
2Topotecan (Hycamtin)FDA LinkGeneric
04/2022 - 10/2021
2ADI PEG20IBA
01/2022 - 01/2021
2Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA
01/2022 - 01/2021
2RNA (Ribonucleic Acid)IBA
07/2021 - 10/2015
2Estrogen Receptor Modulators (Antiestrogen)IBA
01/2021 - 01/2019
2Estrogens (Estrogen)FDA Link
01/2021 - 05/2014
2Cisplatin (Platino)FDA LinkGeneric
01/2021 - 10/2004
2Alkylating AgentsIBA
12/2020 - 02/2014
2Histone Deacetylases (Histone Deacetylase)IBA
11/2020 - 11/2017
2Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2020 - 01/2014
2Mitogen-Activated Protein KinasesIBA
01/2020 - 05/2014

Therapy/Procedure

108Therapeutics
01/2022 - 10/2004
13Immunotherapy
01/2022 - 12/2017
12Drug Therapy (Chemotherapy)
01/2022 - 01/2014
9Precision Medicine
03/2021 - 12/2008
4Time-to-Treatment
10/2021 - 02/2015
3Aftercare (After-Treatment)
01/2022 - 01/2012